<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699176</url>
  </required_header>
  <id_info>
    <org_study_id>19434</org_study_id>
    <nct_id>NCT03699176</nct_id>
  </id_info>
  <brief_title>Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids</brief_title>
  <acronym>ASTEROID 7</acronym>
  <official_title>A Randomized, Parallel-group, Double-blind Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to show superiority of vilaprisan in the treatment of
      heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo.The
      secondary objectives of this study are to additionally evaluate the efficacy and safety of
      vilaprisan in subjects with uterine fibroids.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patient was recruited, study withdrawn for feasibility reasons.
  </why_stopped>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Actual">December 25, 2019</completion_date>
  <primary_completion_date type="Actual">December 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amenorrhea (yes/no)</measure>
    <time_frame>Up to 24 weeks (The last 28 days of treatment period 2)</time_frame>
    <description>Defined as menstrual blood loss (MBL) &lt;2 mL (based on menstrual pictogram)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heavy menstrual bleeding (HMB) response (yes/no)</measure>
    <time_frame>Up to 24 weeks (the last 28 days of treatment period 2)</time_frame>
    <description>Defined as blood loss &lt;80.00 mL during the last 28 days of treatment and &gt;50% reduction compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of amenorrhea</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Onset of amenorrhea is defined by the first day for which the menstrual blood loss for all subsequent 28-day periods up to the end of the treatment period is &lt;2mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of controlled bleeding</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Onset of controlled bleeding is defined by the first day for which the menstrual blood loss for all subsequent 28-day periods up to the end of the treatment period is &lt;80.00 mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of bleeding (spotting allowed) based on the Uterine Fibroid Daily Bleeding Diary (UF-DBD)</measure>
    <time_frame>Up to 24 weeks (the last 28 days of treatment period 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial histology (eg, benign endometrium, presence or absence of hyperplasia or malignancy)</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Vilaprisan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 treatment periods of 12 weeks without a break</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 treatment periods of 12 weeks without a break</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilaprisan (BAY1002670)</intervention_name>
    <description>2 mg, once daily, oral</description>
    <arm_group_label>Vilaprisan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily, oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women, 18 years or older at the time of Visit 1

          -  Diagnosis of uterine fibroid(s) documented by ultrasound at screening with at least 1
             fibroid with largest diameter of ≥ 30 mm (alternatively, of 30 mm or more)

          -  Heavy menstrual bleeding (HMB) in at least 2 bleeding periods during the screening
             period each with blood loss volume of &gt;80.00 mL documented by the menstrual pictogram
             (MP)

          -  Use of an acceptable non-hormonal method of contraception

          -  An endometrial biopsy performed during the screening period, without significant
             histological disorder such as endometrial hyperplasia (including simple hyperplasia)
             or other significant endometrial pathology

        Exclusion Criteria:

          -  Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation
             before start of treatment)

          -  Hypersensitivity to any ingredient of the study drugs

          -  Hemoglobin values ≤6 g/dL or any condition requiring immediate blood transfusion
             (subjects with hemoglobin values ≤10.9 g/dL will be recommended to use iron
             supplementation)

          -  Any diseases, conditions, or medications that can compromise the function of the body
             systems and could result in altered absorption, excessive accumulation, impaired
             metabolism, or altered excretion of the study drug including

          -  Abuse of alcohol, drugs, or medicines (eg: laxatives)

          -  Undiagnosed abnormal genital bleeding

          -  Any diseases or conditions that might interfere with the conduct of the study or the
             interpretation of the results
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Funabashi Municipal Medical Center</name>
      <address>
        <city>Funabashi</city>
        <state>Chiba</state>
        <zip>273-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsudo City General Hospital</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>270-2296</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ena Odori Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Memorial Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahi clinic</name>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <zip>760-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unoki Clinic</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

